• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

lois@unimelb.edu.au

Credentials


Position
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0001-6137-9171

Prof Sherene Loi

Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology

394 Scholarly works
34 Projects

HIGHLIGHTS

  • 2026

    Journal article

    The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial.
    DOI: 10.1093/jnci/djag095
  • 2026

    Journal article

    Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer
    DOI: 10.1038/s41571-026-01120-7
  • 2026

    Research grants (ARC, NHMRC, MRFF)

    Innovating in Breast Cancer Immunology Treatment and Prevention
  • 2022

    Journal article

    Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice.
    DOI: 10.1038/s43018-022-00413-x
  • 2021

    Journal article

    Assessment of Ovarian Function in Phase 3 (Neo)adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation.
    DOI: 10.1093/jnci/djab111
  • 2018

    Research Grant

    Capture: Circulating Tumour Dna Assessment of Pik3ca to Guide Treatment Response
  • 2018

    Research grants (other domestic)

    2018 NBCF Endowed Chair Program
Sherene Loi

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer
    DOI: 10.1158/1078-0432.CCR-25-0874
  • 2026

    Journal article

    Abstract PD7-11: Impact of neoadjuvant pembrolizumab on ovarian function in young patients with triple-negative breast cancer (TNBC): Longitudinal analysis from NeoSTOP and NeoPACT trials
    DOI: 10.1158/1557-3265.sabcs25-pd7-11
  • 2026

    Journal article

    Abstract PS5-02-28: Safety analysis of phase 3 ASCENT-04 study of sacituzumab govitecan (SG) pembrolizumab (pembro) vs chemotherapy (chemo) pembro for previously untreated PD-L1 metastatic triple-negative breast cancer (mTNBC)
    DOI: 10.1158/1557-3265.sabcs25-ps5-02-28
  • 2026

    Journal article

    Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
    DOI: 10.1056/NEJMoa2508959
  • 2026

    Journal article

    Parity and lactation induce T-cell-mediated breast cancer protection
    DOI: 10.1038/s41586-025-09713-5
  • 2026

    Journal article

    Antigen reactivity defines tissue-resident memory and exhausted T cells in tumors
    DOI: 10.1038/s41590-025-02347-9
  • 2026

    Journal article

    Survival among patients with cancer after a coalmine fire: analysis of registry data in regional Victoria, Australia
    DOI: 10.1136/jech-2025-223952
  • 2025

    Journal article

    Baseline tumour burden and prognosis in breast cancer treated with immune checkpoint inhibitors
    DOI: 10.1016/j.breast.2025.104586

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224